Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06607588

Selection of Resistant Mutations to Dolutegravir in PLWH Treated in Mozambique

Selection of Resistant Mutations to Dolutegravir and Associated Drugs in PLWH Treated in Clinical Practice in Chokwé, Mozambique

Status
Recruiting
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The HIV infection not fully controlled, despite being under antiretroviral treatment, could make virus resistance against the antiretroviral treatments, making hardest the well control of HIV infection. The purpose of this research study is to confirm or deny if a not fully good controlled HIV infection could develop virus resistance against antiretroviral drugs that can difficult the good control of the HIV infection.

Detailed description

This research study consists of a single visit, in which you will be taken an additional vial of blood to analyze the presence or absence of mutations in your virus to HIV drugs. In addition, other HIV infection routine information will be recorded: * Demographic data * HIV infection history data * Virological failure information * Laboratory parameters Resistance tests techniques: Genotyping resistance test will be performed from plasma samples in those patients with viral load over 200 copies/ml, using ultracentrifugation if needed (Inzaule, Seth C et al. J Antimicrob Chemother, 2018). Briefly, RNA will be extracted and HIV-1 pol gene will be amplified, followed by a nested-PCR. Amplification products will be purified, quantified and finally diluted and prepared for sequencing following Illumina DNA Sample Preparation Kit protocol (Illumina, San Diego, CA). Samples will finally be pooled and sequenced in a MiSeq System (Illumina). MiSeq sequences will be downloaded from Basespace (Illumina) and analysed using PASeq (IrsiCaixa,Barcelona,ES), v1.4.18 (https://www.paseq.org). The questionnaire about clinical and demographic characteristics will be performed during the study visit

Conditions

Interventions

TypeNameDescription
OTHERNot applicable- observational studyNot applicable- observational study

Timeline

Start date
2024-10-25
Primary completion
2026-04-01
Completion
2026-09-01
First posted
2024-09-23
Last updated
2025-05-15

Locations

1 site across 1 country: Mozambique

Source: ClinicalTrials.gov record NCT06607588. Inclusion in this directory is not an endorsement.